• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

0.8800 -0.0900 (-9.28%)
Official Closing Price Updated: 8:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 149,200
Open 0.9700
Bid (Size) 0.8800 (1,800)
Ask (Size) 1.020 (20,000)
Prev. Close 0.9700
Today's Range 0.8521 - 0.9700
52wk Range 0.4000 - 3.250
Shares Outstanding 20,821,353
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives Clinical Trials Arena Research and Development Award for Advanced Prostate Cancer
December 17, 2025
Via Investor Brand Network
News headline image
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
December 17, 2025
From Kairos Pharma, Ltd
Via Business Wire

Performance

YTD
+20.7%
+20.7%
1 Month
+8.6%
+8.6%
3 Month
-27.3%
-27.3%
6 Month
+28.4%
+28.4%
1 Year
-9.3%
-9.3%

More News

Read More
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
November 11, 2025
Via Benzinga
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2025 Milestones and Clinical Progress in CEO Letter to Shareholders
November 04, 2025
Via Investor Brand Network
News headline image
Kairos Pharma Provides Shareholder Update
November 04, 2025
From Kairos Pharma Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
October 20, 2025
Via Investor Brand Network
News headline image
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
October 20, 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
October 07, 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
September 19, 2025
Via Benzinga
News headline image
Top movers in Friday's session ↗
September 19, 2025
Via Chartmill
News headline image
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗
September 19, 2025
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
September 18, 2025
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
September 18, 2025
Via Chartmill
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV105 in Prostate Cancer
September 18, 2025
Via Investor Brand Network
News headline image
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
September 18, 2025
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Host KOL Event on Phase 2 ENV105 Prostate Cancer Trial
September 11, 2025
Via Investor Brand Network
News headline image
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
September 11, 2025
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
September 03, 2025
Via Investor Brand Network
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Initial Phase 1 Data of ENV105 at World Lung Cancer Conference
September 03, 2025
Via Investor Brand Network
News headline image
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
September 03, 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗
September 02, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
July 30, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
July 17, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
July 16, 2025
Via Benzinga

Frequently Asked Questions

Is Kairos Pharma, Ltd. Common Stock publicly traded?
Yes, Kairos Pharma, Ltd. Common Stock is publicly traded.
What exchange does Kairos Pharma, Ltd. Common Stock trade on?
Kairos Pharma, Ltd. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Kairos Pharma, Ltd. Common Stock?
The ticker symbol for Kairos Pharma, Ltd. Common Stock is KAPA on the New York Stock Exchange
What is the current price of Kairos Pharma, Ltd. Common Stock?
The current price of Kairos Pharma, Ltd. Common Stock is 0.8800
When was Kairos Pharma, Ltd. Common Stock last traded?
The last trade of Kairos Pharma, Ltd. Common Stock was at 01/09/26 08:00 PM ET
What is the market capitalization of Kairos Pharma, Ltd. Common Stock?
The market capitalization of Kairos Pharma, Ltd. Common Stock is 18.32M
How many shares of Kairos Pharma, Ltd. Common Stock are outstanding?
Kairos Pharma, Ltd. Common Stock has 18M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap